mRNA technology Archives

Valneva, Vaccine, vaccine development, vaccine developer

News and Trends 15 Jun 2022

Eurocine Vaccines expands portfolio to develop HSV-2 vaccine

Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2), based on technologies developed by Swiss biotech company Redbiotec. The agreement covers both an mRNA […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […]

June 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 May 2022

Therapeutic RNA company receives additional funding

UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP […]

May 31, 2022 - 2 minutesmins - By Jim Cornall

ethris mrna therapy respiratory infection

News and Trends 1 Feb 2022

Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA

Thanks to Covid-19 vaccines, messenger RNA (mRNA) technology has reached the mainstream. With a €23.4M Series B round, the German firm Ethris is riding the mRNA buzz by developing inhalable mRNA therapies for respiratory diseases. As Covid-19 mRNA vaccines entered the market for the first time in 2020, the wide potential of mRNA technology became […]

February 1, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Aug 2021

Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology

Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA therapies for a range of conditions, including respiratory, liver, and infectious diseases. The company’s €2.7B ($3.2B) buyout, announced by Sanofi earlier this month, seems a […]

August 17, 2021 - 5 minutesmins - By Mark Zipkin

covid 19 vaccine patent waiver intellectual property ip

News and Trends 15 Jun 2021

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […]

June 15, 2021 - 5 minutesmins - By Anita Chakraverty

Ziphius Vaccines Covid 19 pandemic vaccine treatment

News and Trends 1 Jun 2021

Next-Generation mRNA Vaccine Technology Unveiled in Series A Round

Messenger RNA vaccines have been at the forefront of the global struggle against the Covid-19 pandemic over the past year. Now scientists are working to upgrade the technology: enter the stage of saRNA, or self-amplifying RNA vaccines. Among the frontrunners to introduce saRNA technology is the Belgian startup Ziphius Vaccines, which recently raised €29.3M to […]

June 1, 2021 - 4 minutesmins - By Victor Kotsev

mRNA DNA race Covid 19 vaccine BioNTech Pfizer

News and Trends 22 Dec 2020

EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19

BioNTech and Pfizer’s Covid-19 vaccine, made from messenger RNA, has become the first of its kind to be approved by the EMA. The EMA has granted conditional approval to Comirnaty, a vaccine against Covid-19 developed by BioNTech and Pfizer. The approval comes weeks after the UK became the first country in the world to approve […]

December 22, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2020

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […]

April 2, 2020 - 3 minutesmins - By Anita Chakraverty

In Depth 30 Mar 2020

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […]

March 30, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 17 Mar 2020

CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute

The German biotech CureVac — which is developing an mRNA vaccine against coronavirus — has been granted up to €80M by the European Commission, shortly after a dispute erupted over an alleged acquisition offer from the US. The money was awarded to help CureVac quickly scale up the production of its candidate Covid-19 vaccine. It […]

March 17, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2019

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

An EU research project has launched with the aim of bringing mRNA treatments to a wider range of patients and diseases. The EXPERT – Expanding Platforms for Efficacious mRNA Therapeutics – project is a collaboration among academics and industry experts from 11 countries who will work on a novel delivery system for messenger (m)RNA therapeutics […]

November 8, 2019 - 4 minutesmins - By External Contributor

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us